SNAP-8
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
SNAP-8 is a synthetic octapeptide marketed as a needle-free topical Botox alternative, blocking SNARE-complex acetylcholine release at nerve endings. Human evidence is weak, drawn mainly from multi-peptide studies; superior-potency claims are untested. The main gap is durability and independence of evidence, not acute danger; risks are mild irritation, but long-term data are scarce. Sold as an FDA-regulated cosmetic ingredient, not an FDA-approved drug.
Read Full recordStudied uses & evidence
Studied uses(6)
Reduction of expression wrinkles (forehead lines, crow's feet, frown lines)
LowSmall human trials show eye-area improvement only; forehead and frown lines are unevidenced.
Superior potency compared to Argireline (Acetyl Hexapeptide-8)
SpeculativeClaim comes from manufacturer data only; no peer-reviewed human comparison trial exists.
Non-invasive Botox-like muscle relaxation without loss of facial expressivity
SpeculativeMechanism-based only; no human EMG or skin-penetration study confirms this effect.
Evidence limits
- Evidence Level
- Moderate
The clinical evidence for SNAP-8 is consistent but limited in scope and rigor. The manufacturer's 28-day in-vivo study in 17 female volunteers is the primary efficacy data source, showing 34.98% mean wrinkle reduction (max -63.13%) at 10% solution, significantly outperforming Argireline (27.05%) and placebo (2.99%). A second manufacturer study at 3% solution showed up to 38% reduction. In vitro, SNAP-8 is approximately 30% more potent than Argireline (IC50 55 vs. 110 microM). Draelos et al. (2016) confirmed statistically significant facial line improvement in a 14-week multi-peptide trial. Shin et al. (2024) demonstrated wrinkle improvement and safety in a 24-subject microneedle delivery study. All studies report excellent safety with no adverse effects. However, there are no large-scale RCTs isolating SNAP-8, no long-term safety data beyond 28 days for the standalone ingredient, and core efficacy claims rest on manufacturer-sponsored data. The evidence is sufficient for cosmetic claims but far below pharmaceutical standards.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
No known serious adverse effects
LowMild skin irritation or redness in sensitive individuals
LowLimited long-term safety data
ModeratePeptide instability and reduced efficacy under improper conditions
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.